PHYLOGICA IMPROVES PHYLOMER POTENCY, HALF-LIFE
August 30th 2008 09:57
Wednesday August 27, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS FLAT: SUNSHINE HEART UP 30%, LABTECH DOWN 15%
* PHYLOGICA IMPROVES PHYLOMER POTENCY, HALF-LIFE
* PORTLAND FOUNDING DIRECTOR DR RON SEKEL RESIGNS
* NEUREN DIVESTS CANCER PROGRAM
* ELLEX PROFIT DOWN 58% TO $1m ON REVENUE UP 13% TO $50m
* VENTRACOR TELLS ASX: RESULTS, FUNDING MAY HAVE PUSHED PRICE
* ANZ CEASES OPES PRIME SUBSTANTIAL IN BIOPROSPECT
* KARMELSONIX APPOINTS MARKETING MANAGERS
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
PHYLOGICA
Phylogica says affinity and half-life extension data “demonstrates the ability of its lead molecules to work as effective drugs”.
Phylogica said data on affinity or potency and half-life extension, improving the circulation times of a drug within the body, has enabled it to meet its next set of Federal Government commercial ready grant milestones.
A Phylogica media release said the milestones “allowed the company to demonstrate that it has assembled all the required pieces of the competitive jigsaw to enable its proprietary Phylomer drug discovery platform to compete on the world stage”.
Phylogica said this was reinforced at two recent US conferences, IBC Beyond Antibodies and IBC Drug Discovery Technology, where Phylogica scientists were invited speakers.
Phylogica said the data generated by its team was of “world-class equivalence and provides significant validation that the Phylogica technology can repeatedly and consistently generate high quality hits that are suitable for drug development”.
Phylogica’s chief scientist, Dr Paul Watt, said the company had demonstrated its Phylomer peptides had favorable half-lives and potency levels.
“Using a combination of standard and in-house techniques, we have been able to improve the effective potency of some of our lead molecules several hundred-fold,” Dr Watt said.
He said that a standard half-life extension technology using pegylation or the attachment of polyethylene glycol (PEG) was used to “extend circulation time in rats significantly, without losing efficacy of the molecule”.
“These improvements in drug-like characteristics of peptides such as Phylomers are important for their commercial viability, in order to allow a realistic cost-of-goods per dose and tolerable administration regimes for patients,” Phylogica said.
Such improvements were also important for extended administration, which was important for treatment of chronic diseases such as rheumatoid arthritis and irritable bowel disorder.
Phylogica’s deputy chairman, Harry Karelis said the data completed the “jigsaw puzzle for Phylogica, proving that our drug leads can be easily modified to meet industry standards”.
“With these validating experiments successfully concluded the company is now well placed to continue to showcase its technology to logical partners,” Mr Karelis said.
“As more and more drugs undergo patent expiry the pharmaceutical industry is increasingly looking for next generation technologies that can help address rapidly dwindling drug pipelines,” he said.
“With our extensive patent estate and growing data pack the level of interest from third parties wishing to access the company’s technology continues to increase,” Mr Karelis said.
Phylogica was up 0.3 cents or 3.85 percent to 8.1 cents.
subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 22 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
